Rite Aid might fail to ‘continue as an operating company’

Rite Aid Corp (NYSE: RAD) is down 25% in the stock market on Thursday after a Deutsche Bank analyst said the drugstore chain might fail to continue as an “operating company”.

George Hill has $1.0 a share price target

George Hill downgraded the stock this morning to “sell” with a price target of $1.0 a share – an 85% downside from here.

According to Deutsche Bank, Ride Aid needs its adjusted EBITDA for fiscal 2023 to fall in the range of $400 million to $450 million at least to continue as an operating company. The analyst wrote:

At a number below $400 million, the equity arguably has no value as the company is not in a position to generate real returns to shareholders. COVID has hastened the decline of the retail pharmacy segment, and this preliminary 2023 outlook seems unattainable.

Rite Aid Corp is reporting next week

Rite Aid is scheduled to report its Q4 results and guide for fiscal 2023 on April 14th. In December, the Pennsylvania-headquartered company had forecast its full-year adjusted EBITDA “significantly above” $430 million.

Hill, however, estimates a much lower $377 million in adjusted EBITDA for Rite Aid in fiscal 2023. Late last year, Rite Aid identified 63 stores across the United States that it said it will shut down to cut costs and improve profitability.

The stock is down more than 55% for the year.

The post Rite Aid might fail to ‘continue as an operating company’ appeared first on Invezz.

Disclaimer:, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2022 All Rights Reserved.

To Top